Hepatitis B Virus Reactivation in a Case With Non Hodgkin Lymphoma Treated by Rituximab Containing Regimen: Treatment With Dual Anti-Viral Combination

Rituximab is a chimeric monoclonal antibody targeting CD20 expressed on pre-B and mature B lymphocytes. This antibody has been used for a more than 20 years in cases with B cell non-Hodgkin lymphomas (B-NHL). The use of rituximab has some complications and one of the most important complications is Hepatitis B reactivation (HBV-R). HBV-R can lead to severe complications like hepatitis reactivation and death. Here we present a case with B-NHL developing HBV reactivation and successful treatment with combined anti-viral treatment.